The Successful and Novel Treatment of Non-Neurogenic Detrusor- External Sphincter Dyssynergia (DESD) with Botulinum Toxin A
|
|
- Magdalene Miller
- 6 years ago
- Views:
Transcription
1 original article The Successful and Novel Treatment of Non-Neurogenic - External Sphincter Dyssynergia (DESD) with Botulinum Toxin A Tricia LC Kuo, MBBS, MRCSEd, M Med (Surg), FAMS, Lay Guat Ng, MBBS, FRCS (Edin), M Med(Surg), FAMS Department of Urology, Urology Centre, Singapore General Hospital Abstract Introduction: Our study aims to examine the treatment outcomes of patients with non-neurogenic detrusorexternal sphincter dyssynergia (DESD) after the injection of botulinum toxin A (BTX-A, Botox ) to the external sphincter. Methods: A retrospective review of nine patients with DESD was performed. All patients were diagnosed with the aid of video urodynamic studies. Pre-operative evaluation was standardised using bladder diary, urine microscopy and culture, bedside ultrasound of the kidneys and bladder, and renal function test. Each received BTX-A injection of U to the external sphincter. The pre-operative and post-operative maximum flow rate (Qmax) and post-void residual urine (PVRU) were objectively compared using paired-samples t test. Results: All the injections were performed from December 2006 to March Of the nine patients, seven (77.8%) were female and two (22.2%) were male. The mean age was 49.2 years (range years). The mean pre-operative maximum flow rate (Qmax) was 9.7±6.26 ml/s. A month later, the post-operative Qmax improved to 16.5±11.3 ml/s. Mean difference in Qmax was 6.76±8.1 ml/s (P = 0.037). The mean preoperative post void residual urine (PVRU) was 179.2±86.8 ml. This improved to 45.7±44.4 ml post-operatively. The mean difference in PVRU of 133.6±77.2 ml (P = 0.001). Conclusion: In patients with DESD, there is a significant improvement in PVRU and Qmax after the injection of BTX-A. Hence, BTX-A injection is an effective method of treatment for DESD. However, further studies and followup are required to further evaluate patient satisfaction, quality of life and need for repeated injections. Keywords: Botulinum toxin, -sphincter dyssynergia, Non-neurogenic detrusor dysfunction INTRODUCTION Botulinum toxin A (BTX-A, Botox ) was first introduced in Urology by Dykstra 1 in 1988 for the treatment of detrusor sphincter dyssynergia in patients with spinal cord injury. Subsequent studies of sphincter spasticity in adult patients had significant positive results, especially decreased PVRU 2-7. The use of BTX-A in children has been further examined, including children with nonneurogenic neurogenic bladder dysfunction, with good outcomes 8-9. Non-neurogenic functional bladder outlet obstruction (in the absence of anatomical abnormality) can arise from sphincter dyssynergia. These may also be termed non-neurogenic neurogenic bladder, Hinman syndrome or external sphincter pseudodyssynergia. Essentially in DESD, there is urodynamic evidence of bladder outlet obstruction, secondary to a kinesiologic disassociation of the two groups of muscles that generally work in harmony (the detrusor and the external sphincter), in the absence of any neurological abnormalities. High voiding s secondary to bladder outlet obstruction can lead to long-term renal damage. As such, traditional treatment modalities for DESD typically aim to reduce voiding s. These options include urethral stents, balloon dilatation Proceedings of Singapore Healthcare Volume 22 Number
2 Original Article Fig. 1. Urodynamic study involuntary contractions of the external urethral sphincter, resulting in high intravesical s during the voiding phase. and external sphincterotomy. Our study aims to show that adult patients with DESD can be treated successfully with the injection of BTX-A to the external sphincter, negating the need for drastic surgical measures. METHODS From December 2006 to March 2008, a total of nine patients were found to have DESD and treated. The treatment records of these patients were reviewed retrospectively. All patients were diagnosed with DESD with the aid of video urodynamic studies (UDS). DESD was recognised by the involuntary contractions of the external urethral sphincter during a detrusor contraction (Fig. 1). The micturating cystogram showed ballooning of proximal urethra, associated with external sphincter pinching (Fig. 2). The dilatation of the proximal urethra in male patients confirmed that the level of obstruction was distal to the level of the prostatic urethra. procedure conducted under GA, with the external sphincter identified under direct vision using a rigid cystoscope. Injections were done at four points, namely the 3, 6, 9 and 12 o clock position, with 25U (diluted to 1ml) of BTX-A at each point. Female patients had the procedure under LA, with the injection done using an insulin syringe at the 3 and 9 o clock position, with 25-50U (diluted to 1 ml). The procedure was done as a day surgery procedure. All patients recovered well and were discharged on the same day. Post-operatively, these patients were assessed at the clinic four to six weeks later using uroflowmetry and bedside ultrasonography. The pre-operative and post-operative Qmax and PVRU were objectively compared using paired-samples t test (SPSS 16.0). A P <0.05 was considered to be statistically significant. Pre-operative evaluation was similar in all patients and standardised. Patients kept a bladder diary, had a bedside ultrasound of the kidneys and bladder, and a renal function test. Urine microscopy and culture was done in all cases to exclude urinary tract infection. Each patient received BTX-A (OnabotulinumtoxinA) injection of U, diluted with normal saline, to the external sphincter under local (LA) or general anaesthesia (GA). Male patients had the Fig. 2. Ballooning of proximal urethra, associated with external sphincter pinching 94
3 Botulinum Toxin on DESD Table 1. Patient Characteristics and Clinical Presentation. Patient Sex Age (years) Symptoms Botulinum toxin dose (units) 1 F 53 Poor stream, dysuria 50 2 F 56 Dysuria, frequency, urgency, nocturia 50 3 F 46 Acute retention of urine (ARU), urgency, pain F 64 Urinary incontinence, pain 50 5 F 43 Hesitancy, pain 50 6 M 20 ARU, hesitancy 50 7 M 56 Weak stream, incomplete voiding F 51 Dysuria 50 9 F 54 Weak stream 100 RESULTS All the injections were performed from December 2006 to March Of the nine patients, seven (77.8%) were female and two (22.2%) were male. The mean age was 49.2 years (range years). Patient characteristics including presenting complaints are shown in Table 1. The mean pre-operative Qmax was 9.7±6.26 ml/s. This improved to 16.5±11.3 ml/s post-operatively. The mean difference in Qmax was 6.76±8.1 ml/s (P=0.037). There is a significant improvement in the pre-operative Qmax compared to the post-operative Qmax (Fig. 3). An uroflow trace demonstrates the dramatic improvement six weeks after treatment (Fig. 4). Similarly, we compared the PVRU before and after treatment. The mean preoperative PVRU was 179.2±86.8 ml. This improved to 45.7±44.4 ml post-operatively. The mean difference in PVRU was 133.6±77.2 ml (P=0.001). The difference is also statistically significant (Fig. 5). A summary all urodynamic findings is as shown in Table 2. At subsequent follow-up, four out of nine patients (44.4%) required repeated injections of BTX-A into the external sphincter. The mean time interval between the first and second injection was 9.5 months (range 4 14 months), and the time interval between the second and third injection was 11 months (range 2 23 months). None of the patients suffered from adverse events, for example, stress incontinence, urinary tract infections or bleeding post-operatively. DISCUSSION In today s urologic practice, BTX-A is widely established as part of the armamentarium for the treatment of refractory detrusor overactivity (DO). A multi-centre trial involving 10 European centres, showed an improvement in continence and quality of life after treatment 10. Local experience in managing neurogenic DO in patients with spinal cord injury with injection of BTX-A has also shown good results. There were improvements in continence, bladder capacity, decreased maximal detrusor s and better patient satisfaction 11. At our institution, we previously evaluated the use of BTX-A as a treatment of idiopathic detrusor over-activity for 19 patients with symptoms of overactive bladder. Our prospective study showed improvement in both subjective and objective measurements posttreatment 12. Fig. 3. Changes in Qmax after injection of BTX-A The mechanism of action of BTX-A is through the inhibition of signal transmission at the neuromuscular junction. Botulinum toxin is 95
4 Original Article Before Injection After Injection Fig. 4. Uroflow of a patient before and after treatment with BTX-A Treatment is needed to prevent recurrent urinary tract infections and upper tract complications, particularly if the patient has high detrusor leak point s (DLPP) 15. However, the use of BTX-A for the treatment of non-neurogenic DESD in adult patients is not common. Fig. 5. Changes in PVRU after injection of BTX-A produced by the bacteria Clostridium botulinum. There are four genetically distinct groups of the anaerobe that produce seven different immunogenic toxins, labelled A to G. The active, dichain polypeptide form of botulinum toxin consists of a heavy chain (~100 kda) connected by a disulfide bond to a light chain (~50kDa) with an associated zinc (Zn) atom. BTX-A cleaves synaptosomal-associated protein (SNAP-25), which prevents exocytosis of neurotransmittercontaining vesicles at the nerve terminal 13,14. Neurogenic DESD typically occur in patients with neurological pathology, for example, spinal cord lesions secondary to spinal cord injury, multiple sclerosis or transverse myelitis. Patients may have elevated intravesical s and PVRU. Non-neurogenic DESD or Hinman syndrome was first described by Hinman in He described the non-neurogenic bladder in 14 boys aged eight years old, who had incontinence, infections and obstructive uropathy 16. Current treatment consists of a combination of antibiotics, anticholinergics, alpha-blockers and bladder training. Clean intermittent self catherisation (CISC) may be required if patients have high PVRU. Steinhardt et al were the first to describe the treatment of external sphincter dyssynergia using botulinum toxin for neurologically normal children 17. This method of treatment was successfully repeated at several other centers in paediatric patients 18,19. Our study aims to study the efficacy of use of botulinum toxin in adult patients. Video urodynamic studies are used to confirm the diagnosis of non-neurogenic DESD. We have elected to conduct this examination without the use of electromyography (EMG) unlike other centres. 96
5 Botulinum Toxin on DESD Table 2. Urodynamic characteristics Patient Pre-operative urodynamic results Post-operative urodynamic results Compliance and presence of a stable bladder Voided volume at opening at Qmax Qmax (mls/s) PVRU Compliance and presence of a stable bladder Voided volume at opening at Qmax Qmax (mls/s) PVRU 1 Normal Normal Normal NA 178 NA NA Normal NA 242 NA NA Normal NA 350 NA NA Normal NA 150 NA NA Normal Normal Abnormal NA 324 NA NA Normal NA 250 NA NA Normal NA 180 NA NA We have found that this approach is less invasive as it eliminates the need for needle electrodes. Surface EMG probes have the disadvantage of being inaccurate due to patient movement. In addition, the fluoroscopic method allows diagnosis of the level of obstruction, thereby allowing the exclusion of bladder outlet obstruction secondary to prostatic enlargement in our male patients. Our results have shown a statistical difference in pre-treatment and post-treatment variables with increase in Qmax, and reduction in PVRU. This shows that BTX-A injection is a feasible form of treatment for non-neurogenic DESD. However, treatment effect may be short-lived in some patients, with some requiring repeated injections (44.4%). This and the incurred cost seem to be the main disadvantage of repeated BTX-A injections. It is observed that in our series, that the time interval between the second and third injection (mean 11 months), is longer than the time interval for the first and second (mean 9.5 months). We also acknowledge the limitations of our study including the small sample size, and the retrospective nature of the study design. Ideally there should be a validated questionnaire evaluating the patient s symptoms pre-procedure and post-procedure. Lately, there has been some concern with regards to the repeated, long-term use of BTX-A intradetrusor injections in patients with neurogenic bladder dysfunction. It is suggested that BTX-A may lead to impaired detrusor contraction strength, which could influence future treatment options 20. Therefore, long-term follow-up is required for this group of patients to ensure that there are no adverse effects or sequelae of repeated injections. CONCLUSION We have successfully demonstrated an objective improvement in Qmax and reduction in PVRU in patients with non-neurogenic DESD after the injection of BTX-A. However, further studies are required to further evaluate subjective patient satisfaction and quality of life. Long-term followup for such patients is also essential as they may require repeat injections. REFERENCES 1. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988;139: Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double blind study. Arch Phys Med Rehabil 1990;71: Schurch B, Hodler J, Rodie B. Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections. J Neurol Neurosurg Psychiatry 1997;63: Petit H, Wiart E, Gaujard E, Le Breton F, Ferriere JM, Lagueny A et al. Botulinum A toxin treatment for detrusor sphincter dyssynergia in spinal cord disease. Spinal Cord 1998;36: de Seze M, Petit H, Gallien P, de Seze MP, Joseph PA, Mazaux JM et al. Botulinum A toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol 2002;42:56. 97
6 Original Article 6. Phelan MW, Franks M, Somogyi GT, Yokoyama T, Fraser MO, Lavelle JP et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 2001;165: Schulte-Baukloh H, Weiss C, Stolze T, Herholz J, Sturzebecher B, Miller K et al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 2005;48: Mokhless I, Gaafar S, Fouda K, Shafik M, Assem A. Botulinum A toxin urethral sphincter injection in children with nonneurogenic neurogenic bladder. J Urol 2006;176: Franco I, Landau-Dyer L, Isom-Batz G, Collett T, Reda EF. The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children. J Urol 2007;178: Schurch B, de Sez M, Denys P, Chartier-Kastler E, Haab F, Everaert K et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized placebo controlled 6-month study. J Urol 2005;174: Tow A, Toh KL, Chan SP, Consigliere D. Botulinum toxin type A for refractory neurogenic detrusor overactivity in spinal cord injured patients in Singapore. Ann Acad Med Singapore 2007;36: Lie KY, Wong M, Ng LG. Botulinum toxin A for idiopathic detrusor overactivity. Ann Acad Med Singapore 2010;39: Smith CP, Chancellor MB. Emerging role of botulinum toxin in the treatment of voiding dysfunction. J Urol 2004;171: Chuang YC, HC Kuo, Chancellor MB. Botulinum toxin for the lower urinary tract. BJU Intl 2010;105: Weld KJ, Graney MJ, Dmochowski RR. Clinical significance of detrusor sphincter dyssynergia type in patients with post-traumatic spinal cord injury. Urology 2000;56: Hinman F. Non-neurogenic neurogenic bladder. Read at annual meeting of American Urological Association, Chicago, Illinois, May 16-20, Steinhardt GF, Naseer S, Cruz OA. Botulinum toxin: novel treatment for dramatic urethral dilatation associated with dysfunctional voiding. J Urol 1997;158: Radojicic ZI, Perovic SV, Milic NM. Is it reasonable to treat refractory voiding dysfunction in children with botulinum A toxin? J Urol 2006;176: Diaz-Soldano D, Maizels M, Houston JTB. Problems with urinary control. Presented at annual meeting of Section of Urology, American Academy of Pediatrics, San Francisco, California, October 20 24, Pannek J, Gocking K, Bersch U. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. BJU Int 2009;104(9):
Botulinum Toxin: Applications in Urology
Botulinum Toxin: Applications in Urology Dr. Lee Jonat, PGY-4 Department of Urologic Sciences University of British Columbia Outline Mechanism of Action Technical Considerations Adverse Events Neurogenic
More informationEFFECTS OF BOTULINUM TOXIN A INJECTIONS IN SPINAL CORD INJURY PATIENTS WITH DETRUSOR OVERACTIVITY AND DETRUSOR SPHINCTER DYSSYNERGIA
J Rehabil Med 2016; 48: 683 687 ORIGINAL REPORT EFFECTS OF BOTULINUM TOXIN A INJECTIONS IN SPINAL CORD INJURY PATIENTS WITH DETRUSOR OVERACTIVITY AND DETRUSOR SPHINCTER DYSSYNERGIA Maping Huang, PhD 1,
More informationGuidelines on Neurogenic Lower Urinary Tract Dysfunction
Guidelines on Neurogenic Lower Urinary Tract Dysfunction (Text update March 2009) M. Stöhrer (chairman), B. Blok, D. Castro-Diaz, E. Chartier- Kastler, P. Denys, G. Kramer, J. Pannek, G. del Popolo, P.
More informationAdult Urodynamics: American Urological Association (AUA)/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Guideline
Adult Urodynamics: American Urological Association (AUA)/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Guideline TARGET POPULATION Eligibility Decidable (Y or N) Inclusion
More information2/9/2008. Men Women. Prevalence of OAB. Men: 16.0% Women: 16.9% Prevalence (%) < Age (years)
Definition Botox for Overactive Bladder Donna Y. Deng Assistant Professor UCSF Department of Urology Urinary urgency With or without urge incontinence Usually with frequency & nocturia International Continence
More informationSummary. Neuro-urodynamics. The bladder cycle. and voiding. 14/12/2015. Neural control of the LUT Initial assessment Urodynamics
Neuro-urodynamics Summary Neural control of the LUT Initial assessment Urodynamics Marcus Drake, Bristol Urological Institute SAFETY FIRST; renal failure, dysreflexia, latex allergy SYMPTOMS SECOND; storage,
More informationA Simplified Technique for Botulinum Toxin Injections in Children With Neurogenic Bladder
A Simplified Technique for Botulinum Toxin Injections in Children With Neurogenic Bladder Maria Paola Pascali, Giovanni Mosiello,* Armando Marciano, Maria Luisa Capitanucci, Antonio Maria Zaccara and Mario
More informationGUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION
GUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION M. Stöhrer (chairman), D. Castro-Diaz, E. Chartier-Kastler, G. Kramer, A. Mattiasson, J-J. Wyndaele Introduction NLUTD (neurogenic lower urinary
More informationNeurogenic bladder. Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder.
Definition: Neurogenic bladder Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder. Types: Nervous system diseases: Congenital: like myelodysplasia like meningocele.
More informationUrinary Aspects of Multiple Sclerosis chronic condition with innovative treatment strategies. Dr. Boris Friedman May 2, 2012 OBJECTIVES
Urinary Aspects of Multiple Sclerosis chronic condition with innovative treatment strategies Dr. Boris Friedman May 2, 2012 OBJECTIVES 1) Definition and classification of MS 2) Interventional radiology
More informationPhysiology & Neurophysiology of lower U.T.
Physiology & Neurophysiology of lower U.T. Classification of voiding dysfunction Evaluation of a child with voiding dysfunction Management Storage Ø Adequate volume of urine Ø At LOW pressure Ø With NO
More informationRecommandations de prise en charge des vessies neurogènes EAU 2006
Annexe 4-1 Recommandations de prise en charge des vessies neurogènes EAU 2006 (Version courte) 685 686 GUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION M. Stöhrer (chairman), D. Castro-Diaz, E.
More informationDysfunctional Voiding Patients: When Do you Give Medication and Why (A Practical approach)
Dysfunctional Voiding Patients: When Do you Give Medication and Why (A Practical approach) Andrew Combs, PA-C Director, Pediatric Urodynamics Division of Pediatric Urology New York Presbyterian-Weill Cornell
More informationOutcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder Michael K. Flynn,* Cindy L. Amundsen, MaryAnn Perevich, Fan Liu and George D. Webster
More informationHospital and Tzu Chi University, Hualien, Taiwan
LUTS (2012) 4, 29 34 ORIGINAL ARTICLE Difficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity Yih-Chou
More informationClinical Study Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive Bladder
Advances in Urology Volume 2009, Article ID 328364, 4 pages doi:10.1155/2009/328364 Clinical Study Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive
More informationHasheminejad Kidney Center (HKC), Iran University of Medical Sciences (IUMS), Tehran, Iran
ORIGINAL ARTICLE Vol. 43 (6): 1122-1128, November - December, 2017 doi: 10.1590/S1677-5538.IBJU.2016.0622 Abobotulinum - a toxin injection in patients with refractory idiopathic detrusor overactivity:
More informationTuesday 24 June Poster Session 1: Voiding Dysfunction Chairmen: C. Chapple and L. Stewart
Tuesday 24 June 10.30 11.30 Poster Session 1: Voiding Dysfunction Chairmen: C. Chapple and L. Stewart P001 Can oral antibiotic prophylaxis reduce the rate of infection after conventional urodynamic studies?
More informationPhiladelphia College of Osteopathic Medicine. Victoria J. Kopec Philadelphia College of Osteopathic Medicine,
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Does Treatment With OnabotulinumtoxinA
More informationThe Neurogenic Bladder
The Neurogenic Bladder Outline Brandon Haynes, MD Resident Physician Department of Urology Jelena Svircev, MD Assistant Professor Department of Rehabilitation Medicine Anatomy and Bladder Physiology Bladder
More informationLower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist
Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,
More informationTools for Evaluation. Urodynamics Case Studies. Case 1. Evaluation. Case 1. Bladder Diary SUI 19/01/2018
Urodynamics Case Studies Christopher K. Payne, MD Vista Urology & Pelvic Pain Partners Emeritus Professor of Urology, Stanford University Tools for Evaluation Ears, Eyes, and Brain Bladder diary Stress
More informationNEUROGENIC BLADDER. Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph
NEUROGENIC BLADDER Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph OUTLINE Definition Anatomy and physiology of bladder function Types of neurogenic bladder Assessment and management Complications
More informationMr. GIT KAH ANN. Pakar Klinikal Urologi Hospital Kuala Lumpur.
Mr. GIT KAH ANN Pakar Klinikal Urologi Hospital Kuala Lumpur drgitka@yahoo.com 25 Jan 2007 HIGHLIGHTS Introduction ICS Definition Making a Diagnosis Voiding Chart Investigation Urodynamics Ancillary Investigations
More informationManagement of LUTS after TURP and MIT
Management of LUTS after TURP and MIT Hong Sup Kim Konkuk University TURP & MIT TURP : Gold standard MIT TUIP TUNA TUMT HIFU LASER Nd:YAG, ILC, HoLRP, KTP LUTS after TURP and MIT Improved : about 70% Persistent
More informationVOIDING DYSFUNCTION IN MULTIPLE SCLEROSIS
Urological Neurology Brazilian Journal of Urology Official Journal of the Brazilian Society of Urology Vol. 26 (3): 315-320, May - June, 2000 VOIDING DYSFUNCTION IN MULTIPLE SCLEROSIS CEYHUN OZYURT, ÇAG
More informationBotulinum Toxin Injection for OAB: Indications & Technique
Classification of LUTS Botulinum Toxin Injection for OAB: Indications & Technique Sherif Mourad, MD Professor of Urology, Ain Shams University General Secretary of International Continence President of
More informationgiovanni.montini@aosp.bo.it VD: definition Voiding dysfunction refers to daytime voiding disorders in children who do not have neurologic, anatomic, obstructive, or infectious abnormalities of the urinary
More informationBotulinum-AToxin Detrusor and Sphincter Injection in Treatment of Overactive Bladder Syndrome: Objective Outcome and Patient Satisfaction
European Urology European Urology 48 (2005) 984 990 Botulinum-AToxin Detrusor and Sphincter Injection in Treatment of Overactive Bladder Syndrome: Objective Outcome and Patient Satisfaction Heinrich Schulte-Baukloh
More informationeuropean urology 52 (2007)
european urology 52 (2007) 1729 1735 available at www.sciencedirect.com journal homepage: www.europeanurology.com Neuro-urology Do Repeat Intradetrusor Botulinum Toxin Type A Injections Yield Valuable
More informationPractical urodynamics What PA s need to know. Gary E. Lemack, MD Professor of Urology and Neurology
Practical urodynamics What PA s need to know Gary E. Lemack, MD Professor of Urology and Neurology Urodynamics essential elements Urethral catheter Fill rate Catheter size Intravesical pressure measurements
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationFlowmetry/ pelvic floor electromyographic findings in patients with detrusor overactivity
ORIGINAL ARTICLE Vol. 41 (3): 521-526, May - June, 2015 doi: 10.1590/S1677-5538.IBJU.2014.0204 Flowmetry/ pelvic floor electromyographic findings in patients with detrusor overactivity Farshid Alizadeh
More informationCASES FOR TRAINING OF THE INTERNATIONAL SPINAL CORD INJURY LOWER URINARY TRACT FUNCTION BASIC DATA SET CASE 1
1 CASES FOR TRAINING OF THE INTERNATIONAL SPINAL CORD INJURY LOWER URINARY TRACT FUNCTION BASIC DATA SET CASE 1 35 years old man, who previously has been completely healthy, was shot twice in the neck
More informationDETRUSOR SPHINCTER dyssynergia is inappropriate
340 ORIGINAL ARTICLE Transrectal Ultrasound Guided Transperineal Botulinum Toxin A Injection to the External Urethral Sphincter for Treatment of Detrusor External Sphincter Dyssynergia in Patients With
More informationNeuropathic Bladder. Magda Kujawa Consultant Urologist Stockport NHS Foundation Trust 12/03/2014
Neuropathic Bladder Magda Kujawa Consultant Urologist Stockport NHS Foundation Trust 12/03/2014 Plan Physiology- bladder and sphincter behaviour in neurological disease Clinical consequences of Symptoms
More informationMedical History of Botulinum Toxin
REVIEW ARTICLE BOTULINUM TOXIN TREATMENT OF URETHRAL AND BLADDER DYSFUNCTION Yao-Chi Chuang, 1 Christopher P. Smith, 2 George T. Somogyi, 3 and Michael B. Chancellor 2 Abstract: Botulinum toxin (BTX) is
More informationBOTULINUM TOXIN IN LOWER URINARY TRACT
BOTULINUM TOXIN IN LOWER URINARY TRACT Selcuk Yucel, MD Professor in Urology and Pediatric Urology Acibadem University School of Medicine Department of Uroloy and Pediatric Urology Acibadem University
More informationAdverse Events of Intravesical Botulinum Toxin A Injections for Idiopathic Detrusor Overactivity: Risk Factors and Influence on Treatment Outcome
EUROPEAN UROLOGY 58 (2010) 919 926 available at www.sciencedirect.com journal homepage: www.europeanurology.com Incontinence Adverse Events of Intravesical Botulinum Toxin A Injections for Idiopathic Detrusor
More informationUrodynamics in Neurological Lower Urinary Tract Dysfunction. Mr Chris Harding Consultant Urologist Freeman Hospital Newcastle-upon-Tyne
Urodynamics in Neurological Lower Urinary Tract Dysfunction Mr Chris Harding Consultant Urologist Freeman Hospital Newcastle-upon-Tyne Learning Objectives Review functional neurology relevant to lower
More informationMultiple Sclerosis. Véronique Phé, MD, PhD Pitié-Salpêtrière Academic Hospital Department of Urology Paris 6 University Paris, FRANCE
Queen Square Uro-neurology course, London, UK 20 th -21 st October 2016 Multiple Sclerosis Véronique Phé, MD, PhD Pitié-Salpêtrière Academic Hospital Department of Urology Paris 6 University Paris, FRANCE
More informationGlossary of terms Urinary Incontinence
Patient Information English Glossary of terms Urinary Incontinence Anaesthesia (general, spinal, or local) Before a procedure you will get medication to make sure that you don t feel pain. Under general
More informationBladder dysfunction in ALD and AMN
Bladder dysfunction in ALD and AMN Sara Simeoni, MD Department of Uro-Neurology National Hospital for Neurology and Neurosurgery Queen Square, London 10:15 Dr Sara Simeoni- Bladder issues for AMN patients
More informationVoiding Dysfunction. Yao-Chi Chuang,* Jonathan H. Kaufmann, David D. Chancellor, Michael B. Chancellor and Hann-Chorng Kuo,k
Voiding Dysfunction Bladder Instillation of Liposome Encapsulated OnabotulinumtoxinA Improves Overactive Bladder Symptoms: A Prospective, Multicenter, Double-Blind, Randomized Trial Yao-Chi Chuang,* Jonathan
More informationGUIDELINES ON NEURO-UROLOGY
GUIDELINES ON NEURO-UROLOGY (Text update pril 2014) J. Pannek (co-chair), B. Blok (co-chair), D. Castro-Diaz, G. del Popolo, J. Groen, G. Karsenty, T.M. Kessler, G. Kramer, M. Stöhrer Eur Urol 2009 Jul;56(1):81-8
More informationTHE ACONTRACTILE BLADDER - FACT OR FICTION?
THE ACONTRACTILE BLADDER - FACT OR FICTION? Jacob Golomb Department of Urology Chaim Sheba Medical Center Tel Hashomer NEUROGENIC UNDERACTIVE DETRUSOR Central (complete/incomplete): Spinal cord injury-
More informationWe have heard a great deal about "overactive" bladder recently. But what
BLADDER DYSFUNCTION Differential Diagnosis and Treatment of Impaired Bladder Emptying Naoki Yoshimura, MD, PhD, Michael B. Chancellor, MD Department of Urology, University of Pittsburgh School of Medicine,
More informationOveractive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
More informationBladder Dysfunction in Multiple Sclerosis. by Nancy J. Holland, EdD, RN and Nancy C. Reitman, MA, RN
Clinical Bulletin Information for Health Professionals Bladder Dysfunction in Multiple Sclerosis by Nancy J. Holland, EdD, RN and Nancy C. Reitman, MA, RN Effective bladder management strategies make it
More informationURODYNAMICS IN MALE LUTS: NECESSARY OR WASTE OF TIME?
URODYNAMICS IN MALE LUTS: NECESSARY OR WASTE OF TIME? Andrea Tubaro, MD, FEBU Chairman Department of Urology Sant Andrea Hospital Sapienza University of Rome, Italy Disclosures Consultant, paid speaker,
More informationLower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics. Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital
Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital 01/02/2018 Lower Urinary Tract Symptoms LUTS - one of
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 4: , 2012
1112 Usefulness of total bladder capacity and post void residual urine volume as a predictor of detrusor overactivity with impaired contractility in stroke patients SANG HYUB LEE, JOONG GEUN LEE, GYEONG
More informationBotulinum Toxin Injection: A Review of Injection Principles and Protocols
Review Article Botulinum Toxin Injection International Braz J Urol Vol. 33 (2): 132-141, March - April, 2007 Botulinum Toxin Injection: A Review of Injection Principles and Protocols David E. Rapp, Alvaro
More informationREVIEW ARTICLE. Botulinum-A Toxin s efficacy in the treatment of idiopathic overactive bladder
76 REVIEW ARTICLE Botulinum-A Toxin s efficacy in the treatment of idiopathic overactive bladder Marius Alexandru Moga, 1 Simona Banciu, 2 Oana Dimienescu, 3 Nicusor-Florin Bigiu, 4 Ioan Scarneciu 5 Abstract
More informationWhat should we consider before surgery? BPH with bladder dysfunction. Inje University Sanggye Paik Hospital Sung Luck Hee
What should we consider before surgery? BPH with bladder dysfunction Inje University Sanggye Paik Hospital Sung Luck Hee Diagnostic tests in three categories Recommendation: there is evidence to support
More informationMANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH
MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH INTRODUCTION (1) Part of male sexual reproductive organ Size
More informationHow to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxina
Reviews How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxina Mikolaj Przydacz A F, Tomasz Golabek A,E,F, Piotr Chlosta A,E,F Department of Urology, Jagiellonian
More informationNeurogenic Bladder. Spina Bifida Education Day Conference SBA of Northeastern New York Albany, New York April 14, Eric Levey, M.D.
Neurogenic Bladder Spina Bifida Education Day Conference SBA of Northeastern New York Albany, New York April 14, 2018 Eric Levey, M.D. Pediatrics & Neurodevelopmental Disabilities Chief Medical Officer,
More informationIncontinence. When I was given this topic in urology to discuss with you today I
Incontinence When I was given this topic in urology to discuss with you today I was slightly disappointed. I personally see mostly men for problems such as stones, benign prostatic hyperplasia, prostate
More informationSung-Lang Chen, MD 1, Liu-Ing Bih, MD 2, Yu-Hui Huang, MD 2, Su-Ju Tsai, MD 2, Tzer-Bin Lin, PhD 3 and Yu-Lin Kao, MD 1 ORIGINAL REPORT
J Rehabil Med 2008; 40: 744 748 RIGINAL REPRT EFFECT F SINGLE BTULINUM TXIN A INJECTIN T THE EXTERNAL URETHRAL SPHINCTER FR TREATING DETRUSR EXTERNAL SPHINCTER DYSSYNERGIA IN SPINAL CRD INJURY Sung-Lang
More informationUK Consensus on Bladder Management in MS
Continence Care Forum Annual Conference UK Consensus on Bladder Management in MS Clare J.Fowler National Hospital for Neurology and Neurosurgery & Institute of Neurology, UCL Association of British Neurologists
More informationClinical Study Treatment Strategy According to Findings on Pressure-Flow Study for Women with Decreased Urinary Flow Rate
Advances in Urology Volume 2009, Article ID 782985, 5 pages doi:10.1155/2009/782985 Clinical Study Treatment Strategy According to Findings on Pressure-Flow Study for Women with Decreased Urinary Flow
More informationCase Report Transurethral Incision of the Bladder Neck in a Woman with Primary Bladder Neck Obstruction after Kidney Transplantation
Case Reports in Transplantation Volume 2015, Article ID 312084, 4 pages http://dx.doi.org/10.1155/2015/312084 Case Report Transurethral Incision of the Bladder Neck in a Woman with Primary Bladder Neck
More informationGUIDELINES ON NEURO-UROLOGY
GUIDELINES ON NEURO-UROLOGY (Limited text update March 2015) B. Blok (Co-chair), J. Pannek (Co-chair), D. Castro Diaz, G. del Popolo, J. Groen, T. Gross (Guidelines ssociate), R. Hamid, G. Karsenty, T.M.
More informationVarious Types. Ralph Boling, DO, FACOG
Various Types Ralph Boling, DO, FACOG The goal of this lecture is to increase assessment and treatment abilities for physicians managing urinary incontinence (UI) patients. 1. Effectively communicate with
More informationUse of botulinum toxin for voiding dysfunction
Review Article Use of botulinum toxin for voiding dysfunction David Eldred-Evans, Prokar Dasgupta Department of Urology, Medical Research Council (MRC) Centre for Transplantation, King s College London,
More informationGOVINDARAJ N. RAJKUMAR, DOUGLAS R. SMALL, ABDUL W. MUSTAFA and GRAEME CONN Department of Urology, Southern General Hospital, Glasgow, UK
Original Article BTXA IN DETRUSOR FOR REFRACTORY IDIOPATHIC DOA RAJKUMAR et al. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of
More informationSELECTED POSTER PRESENTATIONS
SELECTED POSTER PRESENTATIONS The following summaries are based on posters presented at the American Urogynecological Society 2004 Scientific Meeting, held July 29-31, 2004, in San Diego, California. CENTRAL
More informationATLAS OF URODYNAMICS. Bladder. Pure. Pves. Pabd. Pdet EMG. Bladder. volume. Cough Strain IDC. Filling. Pure. Pves. Pabd. Pdet EMG
2 Normal Micturition The micturition cycle (urine storage and voiding) is a nearly subconscious process that is under complete voluntary control. Bladder filling is accomplished without sensation and without
More informationURINARY INCONTINENCE. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara
URINARY INCONTINENCE Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara Definition The involuntary loss of urine May denote a symptom, a sign or a condition Symptom the
More informationEMR template and postprocedure notes
EMR template and postprocedure notes Sample autopopulated text to create a BOTOX injection procedure report Information gathered from market research. These considerations are for reference only and should
More informationDysfunctional voiding
Dysfunctional voiding The importance of assessment, diagnosis and treatment of dysfunctional voiding and its role in recurrent UTI Dr Dean Wallace Consultant Paediatric Nephrologist RMCH Objectives Development
More informationIntravesical Botox Injections
Intravesical Botox Injections Department of Urology Patient Information What What is is Botox? Botox? Botox or Botulinum Type-A is toxin produced by bacteria called Clostridium Botulinum. It is given intravesically
More informationOveractive Bladder (OAB) and Quality of Life
Overactive Bladder (OAB) and Quality of Life Dr. Byron Wong MBBS (Sydney), FRCSEd, FRCSEd (Urol), FCSHK, FHKAM (Surgery) Specialist in Urology Central Urology Clinic Hong Kong Continence Society Annual
More informationStimulation of the Sacral Anterior Root Combined with Posterior Sacral Rhizotomy in Patients with Spinal Cord Injury. Original Policy Date
MP 7.01.58 Stimulation of the Sacral Anterior Root Combined with Posterior Sacral Rhizotomy in Patients with Spinal Cord Injury Medical Policy Section Issue 12:2013 Original Policy Date 12:2013 Last Review
More informationManagement, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence
Management, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence Arthur Mourtzinos, MD, MBA Co-Vice Chair, Institute of Urology Director, Continence Center Assistant Professor of Urology,
More informationManaging urinary morbidity after brachytherapy. Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester
Managing urinary morbidity after brachytherapy Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester Themes Can we predict urinary morbidity? Prevention of urinary morbidity
More informationƒ( t, l, c ) The Use of Botox Injection in the Treatment of the Neurogenic Bladder Bladder ( Sphincter ) Dysfunction Dr C K Chan 95%
The Use of Botox Injection in the Treatment of the Neurogenic Bladder Dr C K Chan Division of Urology Department of Surgery Prince of Wales Hospital EAU guidelines 2003 / 2006 Neurologic disease Dementia
More informationPelvic Floor Therapy for the Neurologic Client Carina Siracusa, PT, DPT, WCS
Pelvic Floor Therapy for the Neurologic Client Carina Siracusa, PT, DPT, WCS OhioHealth, Columbus Ohio Disclosures I have nothing to disclose Objectives Describe the role of a pelvic floor therapist in
More informationThe Enlarged Prostate Symptoms, Diagnosis and Treatment
The Enlarged Prostate Symptoms, Diagnosis and Treatment MAC00031-01 Rev G Financial support for this seminar has been provided by NeoTract, Inc., the manufacturer of the UroLift System. 1 Today s Agenda
More informationPRE-OPERATIVE URODYNAMIC
PRE-OPERATIVE URODYNAMIC STUDIES: IS THERE VALUE IN PREDICTING POST-OPERATIVE STRESS URINARY INCONTINENCE IN WOMEN UNDERGOING PROLAPSE SURGERY? Dr K Janse van Rensburg Dr JA van Rensburg INTRODUCTION POP
More informationThe Management of Female Urinary Incontinence. Part 1: Aetiology and Investigations
The Management of Female Urinary Incontinence Part 1: Aetiology and Investigations Dr Oseka Onuma Gynaecologist and Pelvic Reconstructive Surgeon 4 Robe Terrace Medindie SA 5081 Urinary incontinence has
More informationInformation for Patients. Overactive bladder syndrome (OAB) English
Information for Patients Overactive bladder syndrome (OAB) English Table of contents What is the bladder?... 3 What are overactive bladder symptoms?... 3 What causes overactive bladder symptoms?... 3 Diagnosis
More informationLUTS after TURP: How come and how to manage? Matthias Oelke
LUTS after TURP: How come and how to manage? Matthias Oelke Department of Urology Global Congress on LUTD, Rome, 26 th June 2015 Disclosures Consultant, speaker, trial participant and/or research grants
More informationI-STOP TOMS Transobturator Male Sling
I-STOP TOMS Transobturator Male Sling The CL Medical I-STOP TOMS sling for male stress urinary incontinence was developed in France where it is widely used and is the market leader. It is constructed with
More informationUse of the Botulinum Toxin A in the Treatment of the Neurogenic Detrusor Overactivity
Use of the Botulinum Toxin A in the Treatment of the Neurogenic Detrusor Overactivity Editorial Raluca Borcăiaș 1,2, A. Manu-Marin 3, S. Nedelea 1,2, S. Rascu 1,2, V. Jinga 1,2 1 Prof. Dr. Th. Burghele
More information= 0.62, P <0.001) with important clinical exceptions. There was negative correlation between the PV and Qmax (r s
Original Article 60 Relationships between Prostatic Volume and Intravesical Prostatic Protrusion on Transabdominal Ultrasound and Benign Prostatic Obstruction in Patients with Lower Urinary Tract Symptoms
More informationExperience with Different Botulinum Toxins for the Treatment of Refractory Neurogenic Detrusor Overactivity
Neurourology Botulinum Toxins for Refractory Detrusor Overactivity International Braz J Urol Vol. 36 (1): 66-74, January - February, 2010 doi: 10.1590/S1677-55382010000100011 Experience with Different
More informationBotulinum A Toxin and Detrusor Sphincter Dyssynergia: A Double-Blind Lidocaine-Controlled Study in 13 Patients with Spinal Cord Disease
European Urology European Urology 42 2002) 56±62 Botulinum A Toxin and Detrusor Sphincter Dyssynergia: A Double-Blind Lidocaine-Controlled Study in 13 Patients with Spinal Cord Disease Marianne de SeÁze
More informationOveractive bladder can result from one or more of the following causes:
Overactive bladder can affect people of any age; however, it is more common in older people. Effective treatments are available and seeing your doctor for symptoms of overactive bladder often results in
More informationUrodynamic study before and after radical porstatectomy 가톨릭의대성바오로병원김현우
Urodynamic study before and after radical porstatectomy 가톨릭의대성바오로병원김현우 Introduction Radical prostatectomy - treatment of choice for patients with localized prostate cancer. Urinary incontinence and/or
More informationKathleen C. Kobashi, MD, FACS Head, Section of Urology and Renal Transplantation Virginia Mason Medical Center, Seattle, WA
Kathleen C. Kobashi, MD, FACS Head, Section of Urology and Renal Transplantation Virginia Mason Medical Center, Seattle, WA Disclosures Advisory Board and/or Speaker Allergan Medtronic Astellas AUA Guidelines
More informationOriginal Article. Annals of Rehabilitation Medicine INTRODUCTION
Original Article Ann Rehabil Med 2014;38(3):342-346 pissn: 2234-0645 eissn: 2234-0653 http://dx.doi.org/10.5535/arm.2014.38.3.342 Annals of Rehabilitation Medicine Phasic Changes in Bladder Compliance
More informationDiagnosis and Mangement of Nocturia in Adults
Diagnosis and Mangement of Nocturia in Adults Christopher Chapple Professor of Urology Sheffield Teaching Hospitals University of Sheffield Sheffield Hallam University UK 23 rd October 2015 Terminology
More informationAccepted Manuscript. Assessment of renal deterioration and associated risk factors in patients with multiple sclerosis
Accepted Manuscript Assessment of renal deterioration and associated risk factors in patients with multiple sclerosis Nabeel A. Shakir, Arthi Satyanarayan, Jessica Eastman, Benjamin M. Greenberg, Gary
More informationManagement of Female Stress Incontinence
Management of Female Stress Incontinence Dr. Arvind Goyal Associate Professor (Urology& Renal Transplant) Dayanand Medical College & Hospital, Ludhiana, Punjab, India Stress Incontinence Involuntary loss
More informationOnabotulinumtoxinA for the treatment of overactive bladder
OnabotulinumtoxinA for the treatment of overactive bladder Clin. Invest. (2014) 4(3), 281 286 OnabotulinumtoxinA has recently been granted a license for use in overactive bladder (OAB). This review assesses
More informationBotulinum toxin-a for the treatment of overactive bladder: UK contributions
473096URO6210.1177/2051415812473096Journal of Clinical UrologySeth et al. 2013 Original Article Botulinum toxin-a for the treatment of overactive bladder: UK contributions Journal of Clinical Urology 6(2)
More informationP R E S E N T S Dr. Mufa T. Ghadiali is skilled in all aspects of General Surgery. His General Surgery Services include: General Surgery Advanced Laparoscopic Surgery Surgical Oncology Gastrointestinal
More information